| Respiratory

AI-Based Antibody Discovery Platform Identifies Therapeutic mAbs Against Multiple SARS-CoV-2 Strains

Posted by Evotec on Oct 7, 2024 10:18:20 AM

Machine Learning (ML) is becoming critical for the design and development of therapeutics. Just-Evotec Biologics has created a Humanoid Antibody Library for the discovery of biopharmaceuticals that is the first step towards leveraging artificial intelligence and ML.

In this publication we describe how we have started the validation of the library by isolating antibodies against a target of pandemic concern, SARS-CoV-2.

We successfully identified a panel of human monoclonal antibodies that are novel, diverse, and pharmacologically active. These first-generation antibodies exhibited neutralization of SARS-CoV-2 viral infectivity across multiple strains and indicated high developability potential.

These results demonstrate the applicability of our platform for effective therapeutic antibody discovery.

Learn More

0 Comments Click here to read/write comments

Tags: Respiratory, Articles & Whitepapers, Biologics, Structural Biology & Protein Science, Anti-Infectives, Immunology & Inflammation

Achieving Continuous Manufacturing through Equipment Design

Posted by Evotec on Jun 5, 2024 4:42:25 PM

Continuous biomanufacturing is reducing the cost of goods of biopharmaceuticals. Achieving continuous manufacturing requires expertise in equipment design.

Download the highlights of Andrea Isby's presentation at Repligen's DSP Workshop in Estonia from May 23rd, 2024 to learn more.

Download the presentation

0 Comments Click here to read/write comments

Tags: Neuroscience, Respiratory, Oncology, Kidney diseases, Women's health, Presentations, Blog, Formulation & CMC, Biologics, Age-Related Diseases, IND Enabling Studies/Preclinical Development, Anti-Infectives, Immunology & Inflammation, Metabolic Disease & Complications, Rare Diseases, Clinical Development

The Downstream Data Browser

Posted by Evotec on Jun 5, 2024 4:37:18 PM

High-throughput screening methodologies have accelerated downstream development for monoclonal antibodies by enabling parallelized evaluation of chromatographic resins across a range of conditions. However, scientists must now interpret results in a meaningful and consistent way.

Learn how Just - Evotec Biologics' Downstream Data Browser automates visualization of high-throughput datasets, fits response surface statistical models, standardizes report results from a high-throughput screening method and facilitates comparison across molecules allowing the accelerated development of continuous biomanufacturing processes.

Read our poster to learn more

0 Comments Click here to read/write comments

Tags: Neuroscience, Respiratory, Oncology, Kidney diseases, Women's health, Posters, Formulation & CMC, Biologics, Age-Related Diseases, IND Enabling Studies/Preclinical Development, Anti-Infectives, Immunology & Inflammation, Metabolic Disease & Complications, Rare Diseases

Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders

Posted by Evotec on Jun 21, 2023 2:07:20 PM

In this collaborative paper, recently published in J. Med. Chem., 10.1021/acs.jmedchem.2c02087, Chiesi Farmaceutici and Evotec describe the efforts to identify a potent and selective, orally bioavailable, Lysophosphatidic Acid Type 2 (LPA2) Receptor Antagonists to treat Idiopathic pulmonary fibrosis (IPF) or other fibrotic disorders.

The article is an example of how early Dose to Man (eD2M) prediction can be efficiently used to guide Hit to Lead and Lead Optimization when potency and metabolic stability are the main parameters to be optimized. eD2M exploits only in vitro parameters (activity in the primary assay and metabolic stability in human microsomes) and it was extremely useful to monitor project progression and to prioritize compounds for in vivo PK studies. Starting from an LPA2 antagonist compound reported in the literature and following our multiparametric optimization strategy, we were able to identify compound 58, showing a 45000-fold eD2M improvement compared to the starting hit. Additionally, compound 58 exhibits excellent potency, selectivity, and oral in vivo PK profile, making it a suitable tool for probing the involvement of LPA2 receptors in IPF and other fibrotic processes.

IPF is a progressive and fatal disease characterized by lung fibrosis leading to an irreversible decline of the functionality of the lungs. The drugs currently available to patients can slow down the progression of the disease, but there are no treatments that can prevent or block it.

To request a copy of the article, contact the authors. For Evotec: luca.raveglia@evotec.com

0 Comments Click here to read/write comments

Tags: Respiratory, Articles & Whitepapers, Blog

Mouse Pneumonia Model by Acinetobacter baumannii Multidrug Resistant Strains

Posted by Evotec on Dec 21, 2021 2:49:52 PM

Pneumonia induced by multidrug resistant (MDR) Acinetobacter baumannii strains is among the most common and deadly forms of healthcare acquired infections. Animal models play a critical role during the preclinical assessment of novel therapeutic approaches, however, only a self-limiting pneumonia with no or limited local bacterial replication is frequently obtained when MDR A. baumannii is the pathogen.

To strengthen and characterise a sustained lung infection model, in this publication, we focus on:

the ability of intranasal inoculation, intratracheal instillation and oropharyngeal aspiration methods of administration of the bacterial challenge to induce a robust pneumonia in mice
the characterisation of the infection model obtained after intratracheal instillation and oropharyngeal aspiration in terms of histopathological examination of pulmonary lesions, biomarkers of inflammation and leukocytes cells infiltration after treatment with either vehicle or with the antibiotic tigecycline efficacious into reducing lung bacterial load.

LEARN MORE

0 Comments Click here to read/write comments

Tags: Respiratory, Articles & Whitepapers, In vivo Pharmacology

Hydroxyproline Quantitation in Bleomycin-induced Lung Fibrosis Model

Posted by Evotec on Apr 22, 2021 9:22:39 AM

0 Comments Click here to read/write comments

Tags: Respiratory, Posters, In vivo Pharmacology

Inhalation Drug Development Fact Sheet

Posted by Evotec on Mar 29, 2021 8:55:41 PM

Learn more about inhalation drug development at Evotec including:

Integrated and stand-alone development plans tailored to your project
Formulation development of dry powders and liquids designed to meet a quality target product profile (QTPP) with consideration of final commercial process
Inhaled analytics, API, material science, cGMP maufacturing and quality assurance processes

DOWNLOAD

0 Comments Click here to read/write comments

Tags: Respiratory, Fact Sheets, Formulation & CMC